Kisho

Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc. — Rare Disease Pipeline | Kisho | Kisho

Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc.

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
Finnish type amyloidosis	encorafenib	Orphan Designation	-
ovarian cancer	binimetinib	Orphan Designation	-
post 5-alpha-reductase inhibitors treatment syndrome	binimetinib	Orphan Designation	-
post-treatment Lyme disease syndrome	binimetinib	Orphan Designation	-
stage II endometrioid carcinoma	encorafenib	Orphan Designation	-
stage IVb bladder cancer	encorafenib	Orphan Designation	-
treatment-refractory schizophrenia	binimetinib	Orphan Designation	-